Updated on 8 April 2013
Panacea has collaborated extensively to strengthen its presence in US
Panacea Biotec, an Indian firm whose three cardinal business principles have been to focus on innovation, brand building and collaboration, has been extremely committed towards the US market and built an eclectic pipeline of high-barrier-to-entry technology-based generics as well as drug delivery-based NDAs. Panacea, like many other Indian firms is leveraging on big pharma's change in strategy from ‘profit alone' model to ‘profit together' model.
Dr Rajesh Jain, joint managing director, Panacea Biotec, while speaking about the importance of the company's strong pipeline, said that, "In order to fully leverage the potential of such a strong pipeline, it is essential to partner for these products with organizations offering a strong synergy and develop a partnership model that is non-conventional and is win-win in the true sense for both organizations."
In 2012, Panacea collaborated with two companies in the US, including Kreamers Urban and Osmotica Pharmaceutical. Dr Jain mentioned, "Both these partnerships while having distinct and individual flavors from a deal structuring standpoint represent a very strong synergy and win-win business model."
Kremers Urban is a specialty generic business subsidiary of UCB, with an exclusive focus on pharmaceutical products that have a "high-barrier-to-entry." Panacea Biotec announced the strategic alliance with Kremers Urban in the month of November 2012 for 11 high barrier-to-entry generic products in the US market representing an opportunity of $4 billion at the innovator sales level in US.
The first product in this portfolio to reach the market was Tacrolimus capsules, which was launched in the US in November 2012. Panacea Biotec was granted approval of the product from US FDA in September 2012. This would be followed by a series of high-barrier-to-entry generic product launches that are being developed by Panacea Biotec.